Abstract：
OBJECTIVE: Although prospective randomized clinical trials have reported that the use of prophylactic tamoxifen in patients at a high risk of breast cancer is associated with an increased risk of cataracts development, such findings are inconsistent. This study aimed to clarify the relationship between adjuvant tamoxifen use and cataracts risk using a nationwide longitudinal population-based registry.
METHODS: This retrospective cohort study was conducted using the Korean National Health Insurance claims database over a 15-year period (January 2007-December 2021). Data from all female patients diagnosed with ductal carcinoma in situ (DCIS) between 2009 and 2015 were extracted. We evaluated the incidence of cataracts diagnosis and surgery after adjuvant tamoxifen administration in patients with DCIS.
RESULTS: A total of 43,434 patients who met the inclusion criteria were diagnosed with DCIS between 2009 and 2015. Data from 2849 patients receiving tamoxifen and 1615 patients not receiving tamoxifen were analyzed before matching. After matching for comorbidities, type of breast surgery, and age, both groups consisted of 1597 patients. Both before and after matching, adjuvant tamoxifen was not a significant factor for an increased risk of cataracts diagnosis alone or with surgery.
CONCLUSIONS: Our study showed that adjuvant tamoxifen was not a risk factor for increased cataracts diagnosis and surgery in patients with DCIS. This finding provides a basis for physicians to reduce their ocular toxicity concerns regarding the risk of patients developing cataracts by tamoxifen treatment.
METHODS: This retrospective cohort study was conducted using the Korean National Health Insurance claims database over a 15-year period (January 2007-December 2021). Data from all female patients diagnosed with ductal carcinoma in situ (DCIS) between 2009 and 2015 were extracted. We evaluated the incidence of cataracts diagnosis and surgery after adjuvant tamoxifen administration in patients with DCIS.
RESULTS: A total of 43,434 patients who met the inclusion criteria were diagnosed with DCIS between 2009 and 2015. Data from 2849 patients receiving tamoxifen and 1615 patients not receiving tamoxifen were analyzed before matching. After matching for comorbidities, type of breast surgery, and age, both groups consisted of 1597 patients. Both before and after matching, adjuvant tamoxifen was not a significant factor for an increased risk of cataracts diagnosis alone or with surgery.
CONCLUSIONS: Our study showed that adjuvant tamoxifen was not a risk factor for increased cataracts diagnosis and surgery in patients with DCIS. This finding provides a basis for physicians to reduce their ocular toxicity concerns regarding the risk of patients developing cataracts by tamoxifen treatment.
摘要：
目的：虽然前瞻性随机临床试验报道，在乳腺癌高危患者中使用预防性他莫昔芬与白内障发展风险增加有关，这些发现是不一致的。本研究旨在通过全国纵向人群注册来阐明他莫昔芬辅助用药与白内障风险之间的关系。
方法：这项回顾性队列研究是使用韩国国民健康保险索赔数据库进行的，为期15年（2007年1月至2021年12月）。提取了2009年至2015年间诊断为导管原位癌（DCIS）的所有女性患者的数据。我们评估了DCIS患者在接受他莫昔芬辅助治疗后白内障诊断和手术的发生率。
结果：在2009年至2015年期间，共有43,434例符合纳入标准的患者被诊断为DCIS。在匹配之前分析了2849名接受他莫昔芬的患者和1615名未接受他莫昔芬的患者的数据。匹配合并症后，乳房手术的类型，和年龄,两组共1597例患者.匹配之前和之后，辅助他莫昔芬不是单独或手术诊断白内障风险增加的重要因素.
结论：我们的研究表明，他莫昔芬并不是DCIS患者白内障诊断和手术增加的危险因素。这一发现为医生减少对通过他莫昔芬治疗患者患白内障的风险的眼部毒性担忧提供了基础。
方法：这项回顾性队列研究是使用韩国国民健康保险索赔数据库进行的，为期15年（2007年1月至2021年12月）。提取了2009年至2015年间诊断为导管原位癌（DCIS）的所有女性患者的数据。我们评估了DCIS患者在接受他莫昔芬辅助治疗后白内障诊断和手术的发生率。
结果：在2009年至2015年期间，共有43,434例符合纳入标准的患者被诊断为DCIS。在匹配之前分析了2849名接受他莫昔芬的患者和1615名未接受他莫昔芬的患者的数据。匹配合并症后，乳房手术的类型，和年龄,两组共1597例患者.匹配之前和之后，辅助他莫昔芬不是单独或手术诊断白内障风险增加的重要因素.
结论：我们的研究表明，他莫昔芬并不是DCIS患者白内障诊断和手术增加的危险因素。这一发现为医生减少对通过他莫昔芬治疗患者患白内障的风险的眼部毒性担忧提供了基础。
